Literature DB >> 23274319

Surgical management of hepatocellular carcinoma in Child-Pugh class B cirrhotic patients: hepatic resection and/or microwave coagulation therapy versus living donor liver transplantation.

Noboru Harada1, Ken Shirabe, Yasuharu Ikeda, Daisuke Korenaga, Kenji Takenaka, Yoshihiko Maehara.   

Abstract

BACKGROUND: The surgical management of hepatocellular carcinoma (HCC) in cirrhotic patients with Child-Pugh class B remains controversial. The aim of this study was to compare the results of hepatic resection plus microwave coagulation therapy (MCT) versus living donor liver transplantation (LDLT) for HCC in cirrhotic patients with Child-Pugh class B. MATERIAL/
METHODS: Between January 1998 and June 2008, 30 patients underwent hepatic resection plus MCN and 40 patients underwent LDLT for HCC with Child-Pugh class B. Univariate and multivariate Cox proportional hazard models were established. Kaplan-Meier survival curves were generated, and a log-rank test was performed to compare group survival status.
RESULTS: There was no difference in overall survival after hepatic resection plus MCT (1-, 3-, and 5-year: 86.7%, 70.4%, and 70.4%, respectively) compared with LDLT (1-, 3-, and 5-year: 92.5%, 81.5%, and 72.6%, respectively). Disease-free survival was significantly better after LDLT compared with hepatic resection plus MCT. On multivariate analyses, the des-gamma-carboxy prothrombin (DCP) level of more 300 mAU/mL was an independent risk factor for overall survival and recurrence of HCC after LDLT. In preoperative Milan criteria met-patients, 5-year overall survival following LDLT was significantly better than that after hepatic resection plus MCT. Incidentally found hepatocellular carcinoma had higher tendency of well differentiated tumor in the explant liver after LDLT.
CONCLUSIONS: In preoperative Milan criteria met-cirrhotic patients with Child-Pugh class B, LDLT was associated with longer disease-free and overall survival than hepatic resection plus MCN. LDLT could not be indicated in the patients with DCP level of more 300 mAU/mL.

Entities:  

Mesh:

Year:  2012        PMID: 23274319     DOI: 10.12659/aot.883689

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  6 in total

1.  Resection or Transplant in Early Hepatocellular Carcinoma.

Authors:  Markus B Schoenberg; Julian N Bucher; Adrian Vater; Alexandr V Bazhin; Jingcheng Hao; Markus O Guba; Martin K Angele; Jens Werner; Markus Rentsch
Journal:  Dtsch Arztebl Int       Date:  2017-08-07       Impact factor: 5.594

2.  Surgery for Hepatocellular Carcinoma in Patients with Child-Pugh B Cirrhosis: Hepatic Resection Versus Living Donor Liver Transplantation.

Authors:  Norifumi Harimoto; Tomoharu Yoshizumi; Yukiko Fujimoto; Takashi Motomura; Youhei Mano; Takeo Toshima; Shinji Itoh; Noboru Harada; Toru Ikegami; Hideaki Uchiyama; Yuji Soejima; Yoshihiko Maehara
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

3.  A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems.

Authors:  Yun-Hsuan Lee; Chia-Yang Hsu; Chen-Wei Chu; Po-Hong Liu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Yi-You Chiou; Han-Chieh Lin; Teh-Ia Huo
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

4.  Long-term outcomes of living-donor liver transplantation, hepatic resection, and local therapy for hepatocellular carcinoma with three <3-cm nodules in a single institute.

Authors:  Masaaki Hidaka; Takanobu Hara; Akihiko Soyama; Tomohiko Adachi; Hajime Matsushima; Takayuki Tanaka; Hideki Ishimaru; Hisamitsu Miyaaki; Kazuhiko Nakao; Susumu Eguchi
Journal:  JGH Open       Date:  2022-06-30

5.  Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study.

Authors:  Yukihiro Watanabe; Masayasu Aikawa; Tomotaka Kato; Kenichiro Takase; Yuichiro Watanabe; Katsuya Okada; Kojun Okamoto; Isamu Koyama
Journal:  Surg Endosc       Date:  2022-10-06       Impact factor: 3.453

Review 6.  Evolving ablative therapies for hepatic malignancy.

Authors:  Smit Singla; Steven N Hochwald; Boris Kuvshinoff
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.